Notch signaling regulates tumor-induced angiogenesis in SPARC-overexpressed neuroblastoma

Angiogenesis

Volumn 16, Issue 1, 2013, Pages 85-100

  Gorantla, Bharathi ^a   Bhoopathi, Praveen ^a   Chetty, Chandramu ^a   Gogineni, Venkateswara Rao ^a   Sailaja, G S ^a   Gondi, Christopher S ^a   Rao, Jasti S ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Angiogenesis; Apoptosis; Neuroblastoma; SPARC

Indexed keywords

CD31 ANTIGEN; FIBROBLAST GROWTH FACTOR; GELATINASE B; NOTCH RECEPTOR; OSTEONECTIN; PLATELET DERIVED GROWTH FACTOR; VASCULOTROPIN;

AIR SAC; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CAPILLARY TUBE; CELL PROLIFERATION; CELLULAR PARAMETERS; CULTURE MEDIUM; DISEASE MODEL; ENDOTHELIAL TUBE FORMATION; ENDOTHELIUM CELL; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NEUROBLASTOMA; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR CELL CULTURE; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CULTURE MEDIA, CONDITIONED; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; HUMANS; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; NEUROBLASTOMA; OSTEONECTIN; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

MUS;

EID: 84871618170     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-012-9301-1     Document Type: Article

References (59)

1. Morowitz MJ, Barr R, Wang Q, King R, Rhodin N, Pawel B et al (2005) Methionine aminopeptidase 2 inhibition is an effective treatment strategy for neuroblastoma in preclinical models. Clin Cancer Res 11(7):2680-2685
2. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, Children's Cancer Group et al (1999) Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. N Engl J Med 341(16):1165-1173
3. Meadows AT, Tsunematsu Y (2000) Late effects of treatment for neuroblastoma. In: Brodeur GM, Sawada T, Tsuchida Y, Voute PA (eds) Neuroblastoma. Elsevier, Amsterdam, pp 561-570
4. Meitar D, Crawford SE, Rademaker AW, Cohn SL (1996) Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J Clin Oncol 14(2):405-414
5. Brekken RA, Sage EH (2000) SPARC, a matricellular protein: at the crossroads of cell-matrix. Matrix Biol 19(7):569-580
6. Martinek N, Shahab J, Sodek J, Ringuette M (2007) Is SPARC an evolutionarily conserved collagen chaperone? J Dent Res 86(4):296-305
7. Framson PE, Sage EH (2004) SPARC and tumor growth: where the seed meets the soil? J Cell Biochem 92(4):679-690
8. Bradshaw AD, Sage EH (2001) SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J Clin Invest 107(9):1049-1054
9. Sage H, Johnson C, Bornstein P (1984) Characterization of a novel serum albumin-binding glycoprotein secreted by endothelial cells in culture. J Biol Chem 259(6):3993-4007
10. Chlenski A, Guerrero LJ, Peddinti R, Spitz JA, Leonhardt PT, Yang Q et al (2010) Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors. Mol Cancer 9:138
11. Yunker CK, Golembieski W, Lemke N, Schultz CR, Cazacu S, Brodie C et al (2008) SPARC-induced increase in glioma matrix and decrease in vascularity are associated with reduced VEGF expression and secretion. Int J Cancer 122(12):2735-2743
12. Rossler J, Taylor M, Geoerger B, Farace F, Lagodny J, Peschka-Suss R et al (2008) Angiogenesis as a target in neuroblastoma. Eur J Cancer 44(12):1645-1656
13. Eggert A, Ikegaki N, Kwiatkowski J, Zhao H, Brodeur GM, Himelstein BP (2000) High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin Cancer Res 6(5):1900-1908
14. Engebraaten O, Schwachenwald R, Valen H, Bjerkvig R, Laerum OD, Backlund EO (1992) Effects of high and low single dose irradiation on glioma spheroid invasion into normal rat brain tissue in vitro. Anticancer Res 12(5):1501-1506
15. Li T, Zeng ZC, Wang L, Qiu SJ, Zhou JW, Zhi XT et al (2011) Radiation enhances long-term metastasis potential of residual hepatocellular carcinoma in nude mice through TMPRSS4-induced epithelial-mesenchymal transition. Cancer Gene Ther 18:617-626
16. Karar J, Maity A (2009) Modulating the tumor microenvironment to increase radiation responsiveness. Cancer Biol Ther 8(21):1994-2001
17. Lorusso G, Ruegg C (2008) The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol 130(6):1091-1103
18. Adair JC, Baldwin N, Kornfeld M, Rosenberg GA (1999) Radiation-induced blood-brain barrier damage in astrocytoma: relation to elevated gelatinase B and urokinase. J Neurooncol 44(3):283-289
19. Bivik CA, Larsson PK, Kagedal KM, Rosdahl IK, Ollinger KM (2006) UVA/B-induced apoptosis in human melanocytes involves translocation of cathepsins and Bcl-2 family members. J Invest Dermatol 126(5):1119-1127
20. Heissig B, Rafii S, Akiyama H, Ohki Y, Sato Y, Rafael T et al (2005) Low-dose irradiation promotes tissue revascularization through VEGF release from mast cells and MMP-9-mediated progenitor cell mobilization. J Exp Med 202(6):739-750
21. Hovdenak N, Karlsdottir A, Sorbye H, Dahl O (2003) Profiles and time course of acute radiation toxicity symptoms during conformal radiotherapy for cancer of the prostate. Acta Oncol 42(7):741-748
22. Trog D, Yeghiazaryan K, Fountoulakis M, Friedlein A, Moenkemann H, Haertel N et al (2006) Pro-invasive gene regulating effect of irradiation and combined temozolomide-radiation treatment on surviving human malignant glioma cells. Eur J Pharmacol 542(1-3):8-15
23. Zhai GG, Malhotra R, Delaney M, Latham D, Nestler U, Zhang M et al (2006) Radiation enhances the invasive potential of primary glioblastoma cells via activation of the Rho signaling pathway. J Neurooncol 76(3):227-237
24. Knizetova P, Ehrmann J, Hlobilkova A, Vancova I, Kalita O, Kolar Z et al (2008) Autocrine regulation of glioblastoma cell cycle progression, viability and radioresistance through the VEGF-VEGFR2 (KDR) interplay. Cell Cycle 7(16):2553-2561
25. Zheng M, Morgan-Lappe SE, Yang J, Bockbrader KM, Pamarthy D, Thomas D et al (2008) Growth inhibition and radiosensitization of glioblastoma and lung cancer cells by small interfering RNA silencing of tumor necrosis factor receptor-associated factor 2. Cancer Res 68(18):7570-7578
26. Vicini FA, Kestin L, Huang R, Martinez A (2003) Does local recurrence affect the rate of distant metastases and survival in patients with early-stage breast carcinoma treated with breast-conserving therapy? Cancer 97(4):910-919
27. Lee CG, Heijn M, di Tomaso E, Griffon-Etienne M, Ancukiewicz M, Koike C et al (2000) Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60(19):5565-5570
28. Sofia VI, Martins LR, Imaizumi N, Nunes RJ, Rino J, Kuonen F et al (2010) Low doses of ionizing radiation promote tumor growth and metastasis by enhancing angiogenesis. PLoS ONE 5(6):e11222
29. Bhoopathi P, Chetty C, Gujrati M, Dinh DH, Rao JS, Lakka SS (2010) The role of MMP-9 in the anti-angiogenic effect of secreted protein acidic and rich in cysteine. Br J Cancer 102(3):530-540
30. Chetty C, Lakka SS, Bhoopathi P, Kunigal S, Geiss R, Rao JS (2008) Tissue inhibitor of metalloproteinase 3 suppresses tumor angiogenesis in matrix metalloproteinase 2-down-regulated lung cancer. Cancer Res 68(12):4736-4745
31. Bhoopathi P, Chetty C, Kunigal S, Vanamala SK, Rao JS, Lakka SS (2008) Blockade of tumor growth due to matrix metalloproteinase-9 inhibition is mediated by sequential activation of beta1-integrin, ERK, and NF-kappaB. J Biol Chem 283(3):1545-1552
32. Chetty C, Bhoopathi P, Rao JS, Lakka SS (2009) Inhibition of matrix metalloproteinase-2 enhances radiosensitivity by abrogating radiation-induced FoxM1-mediated G2/M arrest in A549 lung cancer cells. Int J Cancer 124:2468-2477
33. Tivnan A, Tracey L, Buckley PG, Alcock LC, Davidoff AM, Stallings RL (2011) MicroRNA-34a is a potent tumor suppressor molecule in vivo in neuroblastoma. BMC Cancer 11:33
34. Xue Y, Cao R, Nilsson D, Chen S, Westergren R, Hedlund EM et al (2008) FOXC2 controls Ang-2 expression and modulates angiogenesis, vascular patterning, remodeling, and functions in adipose tissue. Proc Natl Acad Sci USA 105(29):10167-10172
35. Bhoopathi P, Gorantla B, Sailaja GS, Gondi CS, Gujrati M, Klopfenstein JD et al (2012) SPARC overexpression inhibits cell proliferation in neuroblastoma and is partly mediated by tumor suppressor protein PTEN and AKT. PLoS ONE 7(5):e36093
36. Xue Y, Chen F, Zhang D, Lim S, Cao Y (2009) Tumor-derived VEGF modulates hematopoiesis. J Angiogenes Res 1:9
37. Hu XB, Feng F, Wang YC, Wang L, He F, Dou GR et al (2009) Blockade of Notch signaling in tumor-bearing mice may lead to tumor regression, progression, or metastasis, depending on tumor cell types. Neoplasia 11(1):32-38
38. Bhoopathi P, Chetty C, Dontula R, Gujrati M, Dinh DH, Rao JS et al (2011) SPARC stimulates neuronal differentiation of medulloblastoma cells via the Notch1/STAT3 pathway. Cancer Res 71(14):4908-4919
39. Kamakura S, Oishi K, Yoshimatsu T, Nakafuku M, Masuyama N, Gotoh Y (2004) Hes binding to STAT3 mediates crosstalk between Notch and JAK-STAT signalling. Nat Cell Biol 6(6):547-554
40. Kluppel M, Wrana JL (2005) Turning it up a Notch: cross-talk between TGF beta and Notch signaling. BioEssays 27(2):115-118
41. Sakurai T, Kudo M (2011) Signaling pathways governing tumor angiogenesis. Oncology 81(Suppl 1):24-29
42. Shi W, Harris AL (2006) Notch signaling in breast cancer and tumor angiogenesis: cross-talk and therapeutic potentials. J Mammary Gland Biol Neoplasia 11(1):41-52
43. Niu G, Wright KL, Huang M, Song L, Haura E, Turkson J et al (2002) Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21(13):2000-2008
44. Wei D, Le X, Zheng L, Wang L, Frey JA, Gao AC et al (2003) Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 22(3):319-329
45. Schust J, Sperl B, Hollis A, Mayer TU, Berg T (2006) Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem Biol 13(11):1235-1242
46. Assifi MM, Hines OJ (2011) Anti-angiogenic agents in pancreatic cancer: a review. Anticancer Agents Med Chem 11(5):464-469
47. Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT (2007) Angiogenesis in brain tumours. Nat Rev Neurosci 8(8):610-622
48. Sharma PS, Sharma R, Tyagi T (2011) VEGF/VEGFR pathway inhibitors as anti-angiogenic agents: present and future. Curr Cancer Drug Targets 11(5):624-653
49. Tugues S, Koch S, Gualandi L, Li X, Claesson-Welsh L (2011) Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer. Mol Aspects Med 32(2):88-111
50. Roy CS, Karmakar S, Banik NL, Ray SK (2012) Targeting angiogenesis for controlling neuroblastoma. J Oncol 2012:782020 (Epub: %2011 Aug 25:782020)
51. Talapatra S, Thompson CB (2001) Growth factor signaling in cell survival: implications for cancer treatment. J Pharmacol Exp Ther 298(3):873-878
52. Gerber HP, McMurtrey A, Kowalski J, Yan M, Keyt BA, Dixit V et al (1998) Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/AKT signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 273(46):30336-30343
53. Wu W, Lee WL, Wu YY, Chen D, Liu TJ, Jang A et al (2000) Expression of constitutively active phosphatidylinositol 3-kinase inhibits activation of caspase 3 and apoptosis of cardiac muscle cells. J Biol Chem 275(51):40113-40119
54. Bhatt AP, Bhende PM, Sin SH, Roy D, Dittmer DP, Damania B (2010) Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/AKT/mTOR-addicted lymphomas. Blood 115(22):4455-4463
55. Zhang B, Cao H, Rao GN (2005) 15(S)-hydroxyeicosatetraenoic acid induces angiogenesis via activation of PI3K-AKT-mTOR-S6K1 signaling. Cancer Res 65(16):7283-7291
56. Li JL, Harris AL (2005) Notch signaling from tumor cells: a new mechanism of angiogenesis. Cancer Cell 8(1):1-3
57. Lynn KD, Udugamasooriya DG, Roland CL, Castrillon DH, Kodadek TJ, Brekken RA (2010) GU81, a VEGFR2 antagonist peptoid, enhances the anti-tumor activity of doxorubicin in the murine MMTV-PyMT transgenic model of breast cancer. BMC Cancer 10:397
58. Jendraschak E, Sage EH (1996) Regulation of angiogenesis by SPARC and angiostatin: implications for tumor cell biology. Semin Cancer Biol 7(3):139-146
59. Hasselaar P, Sage EH (1992) SPARC antagonizes the effect of basic fibroblast growth factor on the migration of bovine aortic endothelial cells. J Cell Biochem 49(3):272-283